SAN DIEGO , June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global clinical
- Dr. Preston Klassen, Executive Vice President, Head of Research and Development, resigning - Dr. Chris Cabell appointed Executive Vice President, Head of Research and Development, and Chief Medical Officer SAN DIEGO , June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO , June 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $50.00 per share, including 825,000 shares sold pursuant
SAN DIEGO , May 28, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena.
SAN DIEGO , May 27, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by Arena.
- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, meeting the high end of targeted enrollment range, topline data expected Q4 2020 - Etrasimod ELEVATE UC Program remains on track - Updated guidance for newly initiated trials, and certain trials in planning
SAN DIEGO , May 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being
SAN DIEGO , May 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 113,175 shares of its common stock to 13 new employees and
SAN DIEGO , May 13, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences. Berenberg Conference USA – Hosting virtual investor meetings on Monday, May 18 RBC Capital Markets
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Preston Klassen , MD, MHS, the Company's Executive Vice President, Head of Research & Development, is scheduled to participate in a virtual fireside chat at the Bank of America Securities 2020